ReviewEuropean journal of pharmacology2018
Nutraceuticals in colorectal cancer: A mechanistic approach.
Review in European journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 58 citations in OpenAlex.
- Probiotics in Cardiometabolic Diseases: Current Evidence, Postbiotic Perspectives, and Future Directions.Journal of microbiology and biotechnology · 2026Review
- Advances in research on the intestinal microbiota in the mechanism and prevention of colorectal cancer (Review).Molecular medicine reports · 2025Review
- Investigation of Lactobacillus Probiotics Derived from Traditional Dairy Products in Eliciting Anti-Tumor Responses in Mouse Colorectal Cancer Model.Iranian journal of medical sciences · 2025Article
- Evodiamine inhibits colorectal cancer cell stemness by disturbing ubiquitin specific protease 4 mediated SOX9 stabilization.Discover oncology · 2025Article
- Does a link exist between oral microbiota and oral squamous cell carcinoma? A review of current insights.Journal of oral microbiology · 2025Review
- Interaction of the Gut Microbiome With Cancer Treatment.Journal of the advanced practitioner in oncology · 2024Review
- The Effects of Different Types of Sleep Disorder on Colorectal Cancer: A Nationwide Population-Based Cohort Study.Cancers · 2023Article
- Antitumor activity of 5-fluorouracil polymeric nanogel synthesized by gamma radiation on a rat model of colon carcinoma: a proposed mechanism.Discover oncology · 2023Article
- Article
- Effect of a Diet Supplemented with Sphingomyelin and Probiotics on Colon Cancer Development in Mice.Probiotics and antimicrobial proteins · 2022Article
- Biological activity of galacto-oligosaccharides: A review.Frontiers in microbiology · 2022Review
- Communication in non-communicable diseases (NCDs) and role of immunomodulatory nutraceuticals in their management.Frontiers in nutrition · 2022Review
- Review
- Preventing Colorectal Cancer through Prebiotics.Microorganisms · 2021Review
- Interaction of alcohol with time of eating on markers of circadian dyssynchrony and colon tissue injury.Chemico-biological interactions · 2020Article
- Anti-tumor activities of probiotics in cervical cancer.Journal of ovarian research · 2020Review
- Alcohol-Induced Immune Dysregulation in the Colon Is Diurnally Variable.Visceral medicine · 2020Article
- Free fatty acids receptors 2 and 3 control cell proliferation by regulating cellular glucose uptake.World journal of gastrointestinal oncology · 2020Article
- Review
- The Role of Probiotics in Colorectal Cancer Management.Evidence-based complementary and alternative medicine : eCAM · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Colorectal cancer (CRC) is one of the most diagnosed cancers in the world. Even though screening, surgery and oncology have greatly advanced, CRC is still one of the leading causes of cancer deaths, with 700,000 annual mortalities in both men and women. Environmental and lifestyle factors brought up by industrialization, such as an altered diet, lack of physical activity, increase in alcohol consumption, and circadian disruption, have greatly affected the burden of CRC. These factors increase the CRC risk, at least partly, by pathologically altering the colonic environment, including composition of the gut microbiota, referred to as dysbiosis. Colonic dysbiosis can promote pro-carcinogenic immune signaling cascades, leading to pro-tumorigenic inflammation, carcinogen production, and altered cellular responses in susceptible host resulting to development and/or progression of CRC. Nutraceuticals such as prebiotic molecules and probiotic bacterial species can help maintain intestinal microbial homeostasis and thus mitigate this pathological processes. Therefore, prebiotics and probiotics can hinder the effects of dysbiosis by encouraging anti-carcinogenic, anti-inflammatory immunity, the maintenance of the intestinal epithelial barrier, pro-apoptotic mechanisms, and carcinogen inactivation. In addition to its implications in preventing CRC, because of the mechanisms affected, nutraceuticals are being discovered as potential adjuncts to immune checkpoint inhibitors in the treatment of CRC. In this review, we provide an overview of the potential implications of prebiotics and probiotics in the prevention and treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.